Document Detail


Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study.
MedLine Citation:
PMID:  23346916     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: To report the follow-up of continuing pregnancies after first-trimester exposure to mifepristone. DESIGN: Observational prospective study. SETTING: France. SAMPLE: Patients exposed to mifepristone during the first 12 weeks of pregnancy. METHODS: Women were included in the study when they or their doctors asked a French pharmacovigilance centre or the Paris Teratogen Information Service about the risk of mifepristone exposure in early pregnancy. Exclusion criteria were requests received after 22 weeks of gestation or subsequent elective termination of pregnancy without a pathological examination of the fetus. Data on maternal history and drug exposure were collected on first contact, and pregnancy outcomes were documented at follow-up. MAIN OUTCOME MEASURES: Rate of major congenital malformations. RESULTS: A total of 105 pregnancies were included, with 46 exposed to mifepristone alone, and 59 exposed to both mifepristone and misoprostol. There were 94 live births (90.4%) and 10 (9.6%) miscarriages (including one with major malformation). Elective termination of pregnancy was performed after the subsequent diagnosis of trisomy 21 in one case. The overall rate of major congenital malformations was 4.2% (95% CI 1.2-10.4%), with two cases among 38 patients exposed to mifepristone alone, and two cases among 57 patients exposed to both mifepristone and misoprostol. CONCLUSIONS: This first prospective study found that the rate of major malformations after first-trimester exposure to mifepristone is only slightly higher than the expected 2-3% rate in the general population. Such findings provide reassuring data for risk evaluation for continuation of pregnancy after mifepristone exposure.
Authors:
N Bernard; E Elefant; P Carlier; M Tebacher; Ce Barjhoux; Ma Bos-Thompson; E Amar; J Descotes; T Vial
Related Documents :
1290426 - The timing of delivery in diabetic pregnancy: a 10-year review.
24445596 - Childhood and parental diagnostic radiological procedures and risk of childhood brain t...
23500506 - Weathering the storm: hurricanes and birth outcomes.
8512046 - Diabetes mellitus and fertility control: contraception management issues.
807986 - Primary congenital aphakia and the rubella syndrome.
23422356 - Evaluation of serum concentrations of interleukin (il)-4, il-10, and il-12 during pregn...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-24
Journal Detail:
Title:  BJOG : an international journal of obstetrics and gynaecology     Volume:  -     ISSN:  1471-0528     ISO Abbreviation:  BJOG     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100935741     Medline TA:  BJOG     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2013 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2013 RCOG.
Affiliation:
Centre Régional de Pharmacovigilance, Hospices Civils de Lyon, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coronary Artery Wall Thickness of the Left Anterior Descending Artery Using High Resolution Transtho...
Next Document:  Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.